Safety, Tolerability, and Pharmacokinetics Study of NDX-1017
Status:
Completed
Trial end date:
2019-09-05
Target enrollment:
Participant gender:
Summary
This Phase 1 randomized, placebo-controlled, double-blinded, first-in-human study will
evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of
NDX-1017 in healthy young and elderly subjects, and elderly subjects with amnestic mild
cognitive impairment (MCI), Alzheimer's disease (mild, mild-to-moderate, or moderate), or
mixed dementia with Alzheimer's and vascular components (mild, mild-to-moderate, or
moderate).
Phase:
Phase 1
Details
Lead Sponsor:
Athira Pharma M3 Biotechnology, Inc.
Collaborators:
Alzheimer's Drug Discovery Foundation Alzheimer’s Drug Discovery Foundation Biotrial Inc.